

N-(5-([2-amino-7-(2-hydroxy-1-methylethyl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]carbonyl)pyridin-3-yl)-2-[4-(trifluoromethyl)phenyl]acetamide;

N-(5-([2-amino-7-(2-hydroxy-1-methylethyl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]carbonyl)pyridin-3-yl)-2-(4-chlorophenyl)acetamide;

5 N-(5-([2-amino-7-(2-hydroxy-1-methylethyl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]carbonyl)pyridin-3-yl)-2-[4-(trifluoromethyl)phenyl]acetamide;

N-(5-([2-Amino-7-(2-hydroxy-1,1-dimethylethyl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]carbonyl)pyridin-3-yl)-2-[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]acetamide;

and

10 N-(5-([7-tert-butyl-7H-pyrrolo[2,3-d]pyrimidin-5-yl]carbonyl)pyridin-3-yl)-2-(4-cyclopropyl-1H-1,2,3-triazol-1-yl)acetamide;

or a pharmaceutically acceptable salt thereof.

21. A pharmaceutical composition comprising a compound of the formula (I) or a pharmaceutically acceptable salt thereof, as defined in any one of the preceding claims 1 to 20, and a pharmaceutically acceptable carrier.

22. A compound of the formula (I) or a pharmaceutically acceptable salt thereof, as defined in any one of claims 1 to 20, for use as a medicament.

20 23. A compound of formula (I) or a pharmaceutically acceptable salt thereof, as defined in any one of claims 1 to 20 for use in the treatment of a disease for which an Trk receptor antagonist is indicated

24. A compound of formula (I) or a pharmaceutically acceptable salt thereof, as defined in any one of claims 1 to 20 for use in the treatment of pain.

25. The use of a compound of the formula (I) or a pharmaceutically acceptable salt or composition thereof, as defined in any one of claims 1 to 20, for the manufacture of a medicament to treat a disease for which an Trk receptor antagonist is indicated

30 26. The use of a compound of the formula (I) or a pharmaceutically acceptable salt or composition thereof, as defined in any one of claims 1 to 20, for the manufacture of a medicament to treat pain.

35 27. A method of treatment of a mammal, to treat a disease for which an Trk receptor antagonist is indicated, comprising treating said mammal with an effective amount of a compound of the formula (I) or a pharmaceutically acceptable salt thereof, as defined in any one of claims 1 to 20.

40 28. A method of treatment of pain in a mammal, comprising treating said mammal with an effective amount of a compound of the formula (I) or a pharmaceutically acceptable salt thereof, as defined in any one of claims 1 to 20.

29. A compound or salt according to any one of claims 1 to 20 for use in a medical treatment in combination with a further drug substance.

N-(5-[[2-amino-7-(2-hydroxy-1-methylethyl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]carbonyl]pyridin-3-yl)-2-[4-(trifluoromethyl)phenyl]acetamide;

N-(5-[[2-amino-7-(2-hydroxy-1-methylethyl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]carbonyl]pyridin-3-yl)-2-(4-chlorophenyl)acetamide;

N-(5-[[2-amino-7-(2-hydroxy-1-methylethyl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]carbonyl]pyridin-3-yl)-2-[4-(trifluoromethyl)phenyl]acetamide;

N-(5-[[2-Amino-7-(2-hydroxy-1,1-dimethylethyl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]carbonyl]pyridin-3-yl)-2-[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]acetamide;

and

N-{5-[(7-tert-butyl-7H-pyrrolo[2,3-d]pyrimidin-5-yl)carbonyl]pyridin-3-yl}-2-(4-cyclopropyl-1H-1,2,3-triazol-1-yl)acetamide;

or a pharmaceutically acceptable salt thereof.

21. A pharmaceutical composition comprising a compound of the formula (I) or a pharmaceutically acceptable salt thereof, as defined in any one of the preceding claims 1 to 20, and a pharmaceutically acceptable carrier.

22. A compound of the formula (I) or a pharmaceutically acceptable salt thereof, as defined in any one of claims 1 to 20, for use as a medicament.

23. A compound of formula (I) or a pharmaceutically acceptable salt thereof, as defined in any one of claims 1 to 20 for use in the treatment of a disease for which an Trk receptor antagonist is indicated.

24. A compound of formula (I) or a pharmaceutically acceptable salt thereof, as defined in any one of claims 1 to 20 for use in the treatment of pain.

25. The use of a compound of the formula (I) or a pharmaceutically acceptable salt or composition thereof, as defined in any one of claims 1 to 20, for the manufacture of a medicament to treat a disease for which an Trk receptor antagonist is indicated.

26. The use of a compound of the formula (I) or a pharmaceutically acceptable salt or composition thereof, as defined in any one of claims 1 to 20, for the manufacture of a medicament to treat pain.

27. A compound or salt according to any one of claims 1 to 20 for use in a medical treatment in combination with a further drug substance.